.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Farmers Insurance
Covington
Queensland Health
Johnson and Johnson
Mallinckrodt
Colorcon
McKinsey
Chubb
Chinese Patent Office

Generated: July 27, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203277

« Back to Dashboard
NDA 203277 describes LAMIVUDINE, which is a drug marketed by Mylan Pharms Inc, Apotex, Lupin Ltd, Cipla Ltd, Aurobindo Pharma Ltd, Apotex Inc, Hetero Labs Ltd V, Silarx Pharms Inc, Appco Pharma Llc, Centaur Pharms Pvt, Pharmacare, Hetero Labs Ltd Iii, Strides Pharma, and Teva Pharms, and is included in twenty-three NDAs. It is available from twenty suppliers. Additional details are available on the LAMIVUDINE profile page.

The generic ingredient in LAMIVUDINE is lamivudine; zidovudine. There are twenty-seven drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the lamivudine; zidovudine profile page.

Summary for NDA: 203277

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details

Pharmacology for NDA: 203277

Suppliers and Packaging for NDA: 203277

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
LAMIVUDINE
lamivudine
TABLET;ORAL 203277 ANDA Camber Pharmaceuticals, Inc. 31722-753 31722-753-06 600 TABLET, FILM COATED in 1 BOTTLE (31722-753-06)
LAMIVUDINE
lamivudine
TABLET;ORAL 203277 ANDA Camber Pharmaceuticals, Inc. 31722-753 31722-753-31 10 TABLET, FILM COATED in 1 BLISTER PACK (31722-753-31)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength150MG
Approval Date:Jan 6, 2014TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength300MG
Approval Date:Jan 6, 2014TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Colorcon
Accenture
Fish and Richardson
Federal Trade Commission
Chinese Patent Office
Cantor Fitzgerald
Harvard Business School
Healthtrust
McKesson
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot